The effect of fish oil supplementation on maternal and neonatal outcomes: a triple-blind, randomized controlled trial

Ostadrahimi, Alireza; Mohammadalizadeh, Sakineh; Mirghafourvand, Mojgan; Farshbaf-Khalili, Shadi; Jafarilar-Agdam, Nayyer; Farshbaf‐Khalili, Azizeh

doi:10.1515/jpm-2016-0037

Cited by 13 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two height measurements were required to be within 0.2 cm for accuracy and precision. Z scores were calculated using the Centers for Disease Control and Prevention (CDC) reference dataOstadrahimi (2017) [57], 6 months follow-up WeightUsing a lever scale with a precision of 0.1 kg (Seca, Germany) HeightUsing a stadiometer table accurate to 0.1 cm in the supine position without shoes and hats…”

Section: Resultsmentioning

confidence: 99%

The effectiveness of ω-3 polyunsaturated fatty acid interventions during pregnancy on obesity measures in the offspring: an up-to-date systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

BackgroundThe potential role of ω-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation during pregnancy on subsequent risk of obesity outcomes in the offspring is not clear and there is a need to synthesise this evidence.ObjectiveA systematic review and meta-analysis of randomised controlled trials (RCTs), including the most recent studies, was conducted to assess the effectiveness of ω-3 LCPUFA interventions during pregnancy on obesity measures, e.g. BMI, body weight, fat mass in offspring.MethodsIncluded RCTs had a minimum of 1-month follow-up post-partum. The search included CENTRAL, MEDLINE, SCOPUS, WHO’s International Clinical Trials Reg., E-theses and Web of Science databases. Study quality was evaluated using the Cochrane Collaboration’s risk of bias tool.ResultsEleven RCTs, from ten unique trials, (3644 children) examined the effectiveness of ω-3 LCPUFA maternal supplementation during pregnancy on the development of obesity outcomes in offspring. There were heterogeneities between the trials in terms of their sample, type and duration of intervention and follow-up. Pooled estimates did not show an association between prenatal intake of fatty acids and obesity measures in offspring.ConclusionThese results indicate that maternal supplementation with ω-3 LCPUFA during pregnancy does not have a beneficial effect on obesity risk. Due to the high heterogeneity between studies along with small sample sizes and high rates of attrition, the effects of ω-3 LCPUFA supplementation during pregnancy for prevention of childhood obesity in the long-term remains unclear. Large high-quality RCTs are needed that are designed specifically to examine the effect of prenatal intake of fatty acids for prevention of childhood obesity. There is also a need to determine specific sub-groups in the population that might get a greater benefit and whether different ω-3 LCPUFA, i.e. eicosapentaenoic (EPA) vs. docosahexanoic (DHA) acids might potentially have different effects.

show abstract

Section: Resultsmentioning

confidence: 99%

The effectiveness of ω-3 polyunsaturated fatty acid interventions during pregnancy on obesity measures in the offspring: an up-to-date systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…While now there seems to be more experimental evidence for DHA in preeclampsia, most studies utilized either pure EPA supplementations or EPA and DHA with higher dose of the former. This trend continues in omega-3 research: a recent triple blind randomized controlled trial studied effects of 180 mg EPA plus 120 mg DHA started at 20 week of pregnancy [ 50 ]. Authors observed some effect on birth weight, but it wasn’t statistically significant.…”

Section: Studies Concerning Association Between Lcpufa and Preeclamentioning

confidence: 99%

Omega-3 Long-Chain Polyunsaturated Fatty Acids and Preeclampsia: Trials Say “No,” but Is It the Final Word?

2017

View full text Add to dashboard Cite

Preeclampsia is a dangerous disorder of pregnancy, defined as hypertension with proteinuria. Its nature remains elusive, and measures of prevention and treatment are limited. Observational studies have suggested that preeclampsia is associated with low intake of omega-3 long-chain polyunsaturated fatty acids (LCPUFA). In recent decades, researchers studied LCPUFA supplementation as a measure to prevent preeclampsia. Most of these trials and later systematic reviews yielded negative results. However, these trials had several important limitations associated with heterogeneity and other issues. Recent research suggests that preeclampsia trials should take into consideration the gender of the fetus (and thus sexual dimorphism of placenta), the positive effect of smoking on preeclampsia prevalence, and the possibility that high doses of LCPUFA mid-term or later may promote the disorder instead of keeping it at bay. In this review, we discuss these issues and future prospects for LCPUFA in preeclampsia research.

show abstract

“…Although some studies have shown the beneficial effects of longchain omega 3 fatty acids in reducing preeclampsia, the current study did not find these benefits and did not evaluate subgroups such as diabetic patients, smokers or pregnant women presenting risk factors for premature labor [37][38][39]. Assumingly, in addition to individual variations that, in our viewpoint, are harder to be evaluated, the DHA: EPA ratio in the formulation was one of the determining factors of the apparently contradictory results.…”

Section: Discussionmentioning

confidence: 66%

The Role Played by Salicylic Acid and Omega 3 in the Placental Vascular Resistance Mechanism: A Pilot Study

Batista¹,

Ribeiro²,

Paiva³

et al. 2019

Clinics Mother Child Health

View full text Add to dashboard Cite

Introduction: Doppler flowmetry of uterine arteries allows identifying women at risk of developing preeclampsia (PE), mainly early preeclampsia; it also facilitates the timely use of prophylaxis. Minidose Acetylsalicylic Acid (ASA) can help preventing/delaying preeclampsia development, as well as reducing its severity and the risk of complications. However, not all patients can use this medication; therefore, it is necessary finding clinical alternatives for pregnant women who do not tolerate ASA, as well as evaluating the possibility of increasing this prophylaxis with new drugsthe use of omega 3 is one of these alternatives. Thus, it is possible assuming that omega use by pregnant women could reduce the vascular resistance of uterine arteries and facilitate placentation. The aim of the current study is to evaluate uterine artery resistance and pulsatility indices, as well as bilateral notch in pregnant women presenting identifiable risk factor for PE development, who use omega 3 in association, or not, with ASA. Methodology: The current research is a randomized-controlled, non-blind, parallel, two-arm, open-label preventive clinical trial. Patients were divided into two groups: group 1-use of ASA; and group 2-use of ASA+omega 3. Omegabased supplementations comprised doses of 400 mg/day in gelatin capsules, at DHA: EPA ratios 2.5:1 and 5.0:1. Results: Patients' mean age was 33.48+4.68 years. Mean pregnancies and childbirths were 1.93+1.30 and 0.59 ± 0.37, respectively. Results of uterine artery Doppler flowmetry were associated with omega and/or ASA use; patients who used ASA in association with omega (ASA+omega) recorded the highest uterine artery resistance and pulsatility indices-results were statistically significant. The comparison between ASA use in association, or not, with omega did not show difference in PE, prematurity, oligohydramnios, IUGR or hospitalization in neonatal ICU frequency. There were no cases of fetal death or Hellp Syndrome in either groups. Conclusion: The omega 3 use in association with ASA has increased the uterine artery resistance and pulsatility indices of the investigated patients; however, it did not make any difference in primary and secondary outcomes.

show abstract

The effect of fish oil supplementation on maternal and neonatal outcomes: a triple-blind, randomized controlled trial

Cited by 13 publications

References 21 publications

The effectiveness of ω-3 polyunsaturated fatty acid interventions during pregnancy on obesity measures in the offspring: an up-to-date systematic review and meta-analysis

The effectiveness of ω-3 polyunsaturated fatty acid interventions during pregnancy on obesity measures in the offspring: an up-to-date systematic review and meta-analysis

Omega-3 Long-Chain Polyunsaturated Fatty Acids and Preeclampsia: Trials Say “No,” but Is It the Final Word?

The Role Played by Salicylic Acid and Omega 3 in the Placental Vascular Resistance Mechanism: A Pilot Study

Contact Info

Product

Resources

About